BioNTech SE - American Depositary Shares (NQ:BNTX)

96.85 -1.45 (-1.48%)

Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Volume	788,137
Open	97.59
Bid (Size)	96.50 (300)
Ask (Size)	101.90 (100)
Prev. Close	98.30
Today's Range	96.60 - 99.49
52wk Range	79.52 - 124.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside? ↗

September 28, 2026

Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase.

Via The Motley Fool

Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success? ↗

September 22, 2026

The company is looking to prove it can achieve significant success outside the coronavirus market.

Via The Motley Fool

Performance

YTD	+0.2%	+0.2%
1 Month	-4.7%	-4.7%
3 Month	+3.1%	+3.1%
6 Month	+8.3%	+8.3%
1 Year	-1.8%	-1.8%

More News

BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? ↗

September 22, 2026

Via The Motley Fool

BioNTech (NASDAQ:BNTX) Falls After Q2 Revenue Miss and Revised Full-Year Guidance ↗

August 04, 2026

Via Chartmill

BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗

September 18, 2026

Via The Motley Fool

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat

September 15, 2026

Via FinancialNewsMedia

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat

September 15, 2026

From MarketNewsUpdates.com

Via GlobeNewswire

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

September 14, 2026

From BioNTech SE

Via GlobeNewswire

Why Pfizer Stock Was so Healthy in August ↗

September 08, 2026

Via The Motley Fool

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗

September 03, 2026

Via The Motley Fool

Is BioNTech Stock a No-Brainer Buy on the Dip? ↗

September 02, 2026

Via The Motley Fool

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

August 27, 2026

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

August 27, 2026

From BioNTech SE

Via GlobeNewswire

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

August 26, 2026

Via FinancialNewsMedia

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

August 26, 2026

From MarketNewsUpdates.com

Via GlobeNewswire

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

August 20, 2026

From BioNTech SE

Via GlobeNewswire

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

August 19, 2026

Via Chartmill

BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock. ↗

August 13, 2026

Via The Motley Fool

BioNTech (BNTX) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

Via The Motley Fool

BioNTech Q2 Earnings Call Highlights ↗

August 04, 2026

Via MarketBeat

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

August 04, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

August 03, 2026

From BioNTech SE

Via GlobeNewswire

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

July 29, 2026

From Pfizer Inc.

Via Business Wire

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

July 29, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring ↗

July 23, 2026

Via The Motley Fool

Frequently Asked Questions

Is BioNTech SE - American Depositary Shares publicly traded?

Yes, BioNTech SE - American Depositary Shares is publicly traded.

What exchange does BioNTech SE - American Depositary Shares trade on?

BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for BioNTech SE - American Depositary Shares?

The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market

What is the current price of BioNTech SE - American Depositary Shares?

The current price of BioNTech SE - American Depositary Shares is 96.85

When was BioNTech SE - American Depositary Shares last traded?

The last trade of BioNTech SE - American Depositary Shares was at 10/01/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.